Niagen Bioscience, Inc. Common Stock (NAGE) Stock
Key stats
- Market cap
- $165.92M
- Price / Earnings ratio
- 16.6x
- EPS (TTM)
- $0.13
- Volume
- Loading
- 52-week high
- $7.28
- 52-week low
- $2.04
Source: third-party data provider, as of November 13, 2026
Compare with NAGE
Recent news

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline
Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline
NAGE

Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
NAGE

Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
NAGE

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
NAGE
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 35.53
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.14
- MACD histogram
- -0.02
- SMA 50
- $2.70
- Price below SMA 50
- EMA 50
- $2.64
- Price below EMA 50
- SMA 200
- $3.76
- Price below SMA 200
- EMA 200
- $3.91
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline
Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to Decline
NAGE

Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
NAGE

Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
Niagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
NAGE

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
NAGE

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
NAGE

Niagen Bioscience to Present at LD Micro 20th Annual Main Event
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
NAGE

Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.
NAGE

Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
NAGE

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
NAGE

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
NAGE
News tone: automated (AI) classification of the article's content, not a price prediction.
About Niagen Bioscience, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert N. Fried | CEO & Director | 1960 |
| Mr. Frank Louis Jaksch Jr. | Co-Founder & Chairman | 1968 |
| Mr. Ozan Pamir C.F.A. | CFO & Principal Accounting Officer | 1992 |
| Mr. Carlos Lopez | Senior VP & General Counsel | 1981 |
| Dr. Andrew Shao Ph.D. | Senior Vice President of Global Regulatory & Scientific Affairs | — |
| Ms. Michiko Kelley | Chief Marketing Officer | — |
| Ms. Chu Yan | Managing Director of Asia Pacific | — |
| Kendall Knysch | Head of Media Relations & Partnerships | — |
| Mr. James Lee | Controller | 1976 |
| Wesley Yu | Vice President of Finance | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 35.53
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.14
- MACD histogram
- -0.02
- SMA 50
- $2.70
- Price below SMA 50
- EMA 50
- $2.64
- Price below EMA 50
- SMA 200
- $3.76
- Price below SMA 200
- EMA 200
- $3.91
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $6.00
- Average
- $6.50
- High
- $7.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -10.9 | +14.3 | +43.1 | +22.8 | -27.0 | +9.5 | -5.6 | -4.4 | -6.4 | -4.6 | ||
| 2026 | -4.2 | -17.1 | -11.6 | +4.6 | -20.4 | -11.6 | +2.1 | -11.3 | -6.7 | -13.1 | -12.5 |



